Caplin Point Laboratories Ltd

Caplin Point Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Caplin Point Laboratories Ltd

₹ 2,038 2.62%
19 May - close price
caplinpoint.net BSE: 524742 NSE: CAPLIPOINT
About

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Key Points

Product Portfolio
The company offers a range of pharmaceutical products, with 4,000+ registered licenses and 650 formulations across 36 therapeutic areas. Its product line includes more than 65% of the drugs on the WHO essential drug list. The portfolio features various forms like tablets, capsules, injections, eye drops, oral liquids, soft gel capsules, ointments, creams, gels, injectable powders, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. [1] [2]

Website BSE NSE
  • Market Cap ₹ 15,493 Cr.
  • Current Price ₹ 2,038
  • High / Low ₹ 2,397 / 1,500
  • Stock P/E 24.2
  • Book Value ₹ 472
  • Dividend Yield 0.29 %
  • ROCE 24.6 %
  • ROE 20.6 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.9% CAGR over last 5 years
  • Company's median sales growth is 19.9% of last 10 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
389 395 410 436 453 459 483 493 502 510 534 543 600
265 269 273 293 308 307 318 331 334 332 345 353 396
Operating Profit 124 127 137 142 145 152 165 162 168 178 189 190 204
OPM % 32% 32% 34% 33% 32% 33% 34% 33% 33% 35% 35% 35% 34%
11 12 21 17 17 19 21 31 26 23 30 34 28
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 11 11 12 14 16 16 17 16 17 16 18 19 19
Profit before tax 124 127 146 145 146 154 168 177 177 184 201 204 213
Tax % 18% 18% 20% 18% 17% 19% 22% 21% 18% 18% 20% 19% 19%
101 104 116 120 121 125 131 140 145 151 160 166 173
EPS in Rs 13.45 13.62 15.13 15.43 16.01 16.31 17.21 18.28 18.76 20.10 20.32 21.56 22.38
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
252 239 402 540 649 863 1,061 1,269 1,467 1,694 1,937 2,187
192 175 276 345 417 603 732 874 1,025 1,142 1,287 1,426
Operating Profit 60 64 125 195 232 260 329 395 442 552 651 761
OPM % 24% 27% 31% 36% 36% 30% 31% 31% 30% 33% 34% 35%
3 4 10 13 19 41 23 38 55 66 92 116
Interest 1 0 1 1 1 0 2 1 1 1 1 1
Depreciation 8 7 13 19 23 32 37 47 45 53 66 73
Profit before tax 53 60 121 188 227 269 314 386 451 564 677 803
Tax % 23% 24% 21% 23% 22% 20% 20% 20% 16% 18% 20% 19%
41 46 96 145 177 215 251 308 377 461 541 650
EPS in Rs 5.43 6.05 12.65 19.15 23.35 28.42 32.03 39.56 49.57 60.19 70.56 84.36
Dividend Payout % 18% 20% 12% 10% 9% 9% 9% 10% 9% 8% 8% 5%
Compounded Sales Growth
10 Years: 25%
5 Years: 16%
3 Years: 14%
TTM: 13%
Compounded Profit Growth
10 Years: 30%
5 Years: 22%
3 Years: 20%
TTM: 20%
Stock Price CAGR
10 Years: 26%
5 Years: 28%
3 Years: 43%
1 Year: -4%
Return on Equity
10 Years: 25%
5 Years: 23%
3 Years: 22%
Last Year: 21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 15 15 15 15 15 15 15 15 15 15 15 15
Reserves 78 113 210 349 582 858 954 1,252 1,649 2,084 2,619 3,571
2 2 1 1 36 113 235 219 222 219 222 5
134 137 133 136 109 139 159 250 305 380 352 454
Total Liabilities 229 267 358 500 743 1,126 1,364 1,736 2,191 2,698 3,208 4,045
113 144 152 169 227 272 305 287 280 453 546 605
CWIP 31 0 3 15 10 20 14 18 221 117 144 209
Investments 0 0 17 47 70 61 11 89 281 376 590 859
85 122 186 269 436 772 1,033 1,343 1,410 1,753 1,928 2,373
Total Assets 229 267 358 500 743 1,126 1,364 1,736 2,191 2,698 3,208 4,045

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
50 42 68 66 83 45 269 337 271 318 432 523
-23 -6 -36 -69 -100 -54 -30 -377 -216 -319 -333 -582
-9 -14 -7 -12 90 80 -24 -41 -28 -38 -38 -46
Net Cash Flow 19 23 25 -14 73 70 215 -81 27 -39 61 -106
Free Cash Flow 24 34 43 18 18 -32 195 246 78 173 241 275
CFO/OP 103% 92% 73% 53% 54% 38% 102% 106% 81% 77% 86% 88%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 8 12 30 85 90 97 96 91 98 117 119 138
Inventory Days 37 57 44 44 47 210 139 149 159 183 159 181
Days Payable 112 168 155 144 76 57 68 102 84 116 103 125
Cash Conversion Cycle -67 -99 -81 -16 61 251 166 138 173 184 175 194
Working Capital Days -128 -114 -29 47 104 167 145 165 144 166 174 263
ROCE % 68% 62% 68% 63% 45% 33% 28% 28% 26% 26% 26% 25%

Insights

In beta
Jun 2015 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Products Registered (Global Licenses)
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Therapeutic Segments Covered
Number
R&D Team Strength (Total Professionals/Scientists)
Number
Market Presence (Number of Countries)
Countries
USFDA Approved ANDAs (Cumulative)
Number
Receivables Days
Days
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
70.63% 70.62% 70.62% 70.62% 70.56% 70.56% 70.56% 70.56% 70.56% 70.57% 70.57% 70.57%
2.68% 3.09% 2.84% 3.33% 3.38% 3.71% 4.86% 5.73% 6.16% 6.51% 6.58% 6.15%
0.27% 0.21% 0.43% 1.08% 1.49% 1.83% 2.11% 2.00% 2.22% 2.10% 2.05% 2.14%
26.44% 26.08% 26.11% 24.95% 24.59% 23.93% 22.48% 21.72% 21.06% 20.82% 20.81% 21.14%
No. of Shareholders 78,95678,06879,43881,40980,41196,12392,70296,38794,16993,75393,70593,896

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls